Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 71

1.

Identification and Confirmation of Potentially Actionable Germline Mutations in Tumor-Only Genomic Sequencing.

Clark DF, Maxwell KN, Powers J, Lieberman DB, Ebrahimzadeh J, Long JM, McKenna D, Shah P, Bradbury A, Morrissette JJD, Nathanson KL, Domchek SM.

JCO Precis Oncol. 2019;3. doi: 10.1200/PO.19.00076. Epub 2019 Aug 19.

PMID:
31511844
2.

Validation of a Next-Generation Sequencing Assay Targeting RNA for the Multiplexed Detection of Fusion Transcripts and Oncogenic Isoforms.

Sussman RT, Oran AR, Paolillo C, Lieberman D, Morrissette JJD, Rosenbaum JN.

Arch Pathol Lab Med. 2019 Jun 18. doi: 10.5858/arpa.2018-0441-OA. [Epub ahead of print]

PMID:
31211614
3.

Longitudinal targeted next-generation sequencing in a patient with acute myeloid leukaemia.

Velu PD, Perl AE, Luger SM, Bagg A, Morrissette JJD.

Br J Haematol. 2019 Sep;186(6):801. doi: 10.1111/bjh.16048. Epub 2019 Jun 17. No abstract available.

PMID:
31206598
4.

Molecular Neuropathology in Practice: Clinical Profiling and Integrative Analysis of Molecular Alterations in Glioblastoma.

Nasrallah MP, Binder ZA, Oldridge DA, Zhao J, Lieberman DB, Roth JJ, Watt CD, Sukhadia S, Klinman E, Daber RD, Desai A, Brem S, O'Rourke DM, Morrissette JJD.

Acad Pathol. 2019 May 27;6:2374289519848353. doi: 10.1177/2374289519848353. eCollection 2019 Jan-Dec.

5.

Gilteritinib induces differentiation in relapsed and refractory FLT3-mutated acute myeloid leukemia.

McMahon CM, Canaani J, Rea B, Sargent RL, Qualtieri JN, Watt CD, Morrissette JJD, Carroll M, Perl AE.

Blood Adv. 2019 May 28;3(10):1581-1585. doi: 10.1182/bloodadvances.2018029496. No abstract available.

6.

Clonal Selection with RAS Pathway Activation Mediates Secondary Clinical Resistance to Selective FLT3 Inhibition in Acute Myeloid Leukemia.

McMahon CM, Ferng T, Canaani J, Wang ES, Morrissette JJD, Eastburn DJ, Pellegrino M, Durruthy-Durruthy R, Watt CD, Asthana S, Lasater EA, DeFilippis R, Peretz CAC, McGary LHF, Deihimi S, Logan AC, Luger SM, Shah NP, Carroll M, Smith CC, Perl AE.

Cancer Discov. 2019 Aug;9(8):1050-1063. doi: 10.1158/2159-8290.CD-18-1453. Epub 2019 May 14.

PMID:
31088841
7.

Genomic Signatures Predict the Immunogenicity of BRCA-Deficient Breast Cancer.

Kraya AA, Maxwell KN, Wubbenhorst B, Wenz BM, Pluta J, Rech AJ, Dorfman LM, Lunceford N, Barrett A, Mitra N, Morrissette JJD, Feldman M, Nayak A, Domchek SM, Vonderheide RH, Nathanson KL.

Clin Cancer Res. 2019 Jul 15;25(14):4363-4374. doi: 10.1158/1078-0432.CCR-18-0468. Epub 2019 Mar 26.

PMID:
30914433
8.

Influence of TP53 Mutation on Survival in Patients With Advanced EGFR-Mutant Non-Small-Cell Lung Cancer.

Aggarwal C, Davis CW, Mick R, Thompson JC, Ahmed S, Jeffries S, Bagley S, Gabriel P, Evans TL, Bauml JM, Ciunci C, Alley E, Morrissette JJD, Cohen RB, Carpenter EL, Langer CJ.

JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.18.00107. Epub 2018 Aug 31.

9.

FBXW7 mutations in acute myeloid leukemia.

Sadigh S, Morrissette JJD, Bagg A.

Leuk Lymphoma. 2019 Jun;60(6):1601-1602. doi: 10.1080/10428194.2018.1537488. Epub 2019 Jan 11. No abstract available.

PMID:
30632836
10.

Validation of a next-generation sequencing oncology panel optimized for low input DNA.

Sussman RT, Shaffer S, Azzato EM, DeSloover D, Farooqi MS, Meyer A, Lieberman DB, Bigdeli A, Paolillo C, Ganapathy K, Sukhadia S, Rosenbaum JN, Daber RD, Morrissette JJD.

Cancer Genet. 2018 Dec;228-229:55-63. doi: 10.1016/j.cancergen.2018.08.004. Epub 2018 Sep 19.

PMID:
30553474
11.

Multiparametric magnetic resonance imaging in the assessment of anti-EGFRvIII chimeric antigen receptor T cell therapy in patients with recurrent glioblastoma.

Wang S, O'Rourke DM, Chawla S, Verma G, Nasrallah MP, Morrissette JJD, Plesa G, June CH, Brem S, Maloney E, Desai A, Wolf RL, Poptani H, Mohan S.

Br J Cancer. 2019 Jan;120(1):54-56. doi: 10.1038/s41416-018-0342-0. Epub 2018 Nov 27.

PMID:
30478409
12.

Clinical Implications of Plasma-Based Genotyping With the Delivery of Personalized Therapy in Metastatic Non-Small Cell Lung Cancer.

Aggarwal C, Thompson JC, Black TA, Katz SI, Fan R, Yee SS, Chien AL, Evans TL, Bauml JM, Alley EW, Ciunci CA, Berman AT, Cohen RB, Lieberman DB, Majmundar KS, Savitch SL, Morrissette JJD, Hwang WT, Elenitoba-Johnson KSJ, Langer CJ, Carpenter EL.

JAMA Oncol. 2019 Feb 1;5(2):173-180. doi: 10.1001/jamaoncol.2018.4305.

PMID:
30325992
13.

Myelofibrosis patients can develop extramedullary complications including renal amyloidosis and sclerosing hematopoietic tumor while otherwise meeting traditional measures of ruxolitinib response.

Babushok DV, Nelson EJ, Morrissette JJD, Joshi S, Palmer MB, Frank D, Cambor CL, Hexner EO.

Leuk Lymphoma. 2019 Mar;60(3):852-855. doi: 10.1080/10428194.2018.1509319. Epub 2018 Sep 19. No abstract available.

PMID:
30227762
14.

Classes of ITD Predict Outcomes in AML Patients Treated with FLT3 Inhibitors.

Schwartz GW, Manning B, Zhou Y, Velu P, Bigdeli A, Astles R, Lehman AW, Morrissette JJD, Perl AE, Li M, Carroll M, Faryabi RB.

Clin Cancer Res. 2019 Jan 15;25(2):573-583. doi: 10.1158/1078-0432.CCR-18-0655. Epub 2018 Sep 4.

PMID:
30181385
15.

Germline duplication of ATG2B and GSKIP genes is not required for the familial myeloid malignancy syndrome associated with the duplication of chromosome 14q32.

Babushok DV, Stanley NL, Morrissette JJD, Lieberman DB, Olson TS, Chou ST, Hexner EO.

Leukemia. 2018 Dec;32(12):2720-2723. doi: 10.1038/s41375-018-0231-9. Epub 2018 Aug 7. No abstract available.

PMID:
30087419
16.

Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non-Burkitt Aggressive B-cell Lymphoma.

Cherng HJ, Sargent RL, Nasta SD, Svoboda J, Schuster SJ, Mato AR, Schrank-Hacker A, Morrissette JJD, Landsburg DJ.

Clin Lymphoma Myeloma Leuk. 2018 Oct;18(10):673-678. doi: 10.1016/j.clml.2018.06.012. Epub 2018 Jun 15.

PMID:
30033208
17.

Epidermal Growth Factor Receptor Extracellular Domain Mutations in Glioblastoma Present Opportunities for Clinical Imaging and Therapeutic Development.

Binder ZA, Thorne AH, Bakas S, Wileyto EP, Bilello M, Akbari H, Rathore S, Ha SM, Zhang L, Ferguson CJ, Dahiya S, Bi WL, Reardon DA, Idbaih A, Felsberg J, Hentschel B, Weller M, Bagley SJ, Morrissette JJD, Nasrallah MP, Ma J, Zanca C, Scott AM, Orellana L, Davatzikos C, Furnari FB, O'Rourke DM.

Cancer Cell. 2018 Jul 9;34(1):163-177.e7. doi: 10.1016/j.ccell.2018.06.006.

18.

Genetic Inactivation of CD33 in Hematopoietic Stem Cells to Enable CAR T Cell Immunotherapy for Acute Myeloid Leukemia.

Kim MY, Yu KR, Kenderian SS, Ruella M, Chen S, Shin TH, Aljanahi AA, Schreeder D, Klichinsky M, Shestova O, Kozlowski MS, Cummins KD, Shan X, Shestov M, Bagg A, Morrissette JJD, Sekhri P, Lazzarotto CR, Calvo KR, Kuhns DB, Donahue RE, Behbehani GK, Tsai SQ, Dunbar CE, Gill S.

Cell. 2018 May 31;173(6):1439-1453.e19. doi: 10.1016/j.cell.2018.05.013. Epub 2018 May 31.

19.

Disruption of TET2 promotes the therapeutic efficacy of CD19-targeted T cells.

Fraietta JA, Nobles CL, Sammons MA, Lundh S, Carty SA, Reich TJ, Cogdill AP, Morrissette JJD, DeNizio JE, Reddy S, Hwang Y, Gohil M, Kulikovskaya I, Nazimuddin F, Gupta M, Chen F, Everett JK, Alexander KA, Lin-Shiao E, Gee MH, Liu X, Young RM, Ambrose D, Wang Y, Xu J, Jordan MS, Marcucci KT, Levine BL, Garcia KC, Zhao Y, Kalos M, Porter DL, Kohli RM, Lacey SF, Berger SL, Bushman FD, June CH, Melenhorst JJ.

Nature. 2018 Jun;558(7709):307-312. doi: 10.1038/s41586-018-0178-z. Epub 2018 May 30.

20.

JAK2 V617F-positive acute myeloid leukaemia (AML): a comparison between de novo AML and secondary AML transformed from an underlying myeloproliferative neoplasm. A study from the Bone Marrow Pathology Group.

Aynardi J, Manur R, Hess PR, Chekol S, Morrissette JJD, Babushok D, Hexner E, Rogers HJ, Hsi ED, Margolskee E, Orazi A, Hasserjian R, Bagg A.

Br J Haematol. 2018 Jul;182(1):78-85. doi: 10.1111/bjh.15276. Epub 2018 May 16.

PMID:
29767839
21.

Co-targeting BET and MEK as salvage therapy for MAPK and checkpoint inhibitor-resistant melanoma.

Echevarría-Vargas IM, Reyes-Uribe PI, Guterres AN, Yin X, Kossenkov AV, Liu Q, Zhang G, Krepler C, Cheng C, Wei Z, Somasundaram R, Karakousis G, Xu W, Morrissette JJ, Lu Y, Mills GB, Sullivan RJ, Benchun M, Frederick DT, Boland G, Flaherty KT, Weeraratna AT, Herlyn M, Amaravadi R, Schuchter LM, Burd CE, Aplin AE, Xu X, Villanueva J.

EMBO Mol Med. 2018 May;10(5). pii: e8446. doi: 10.15252/emmm.201708446.

22.

In vivo evaluation of EGFRvIII mutation in primary glioblastoma patients via complex multiparametric MRI signature.

Akbari H, Bakas S, Pisapia JM, Nasrallah MP, Rozycki M, Martinez-Lage M, Morrissette JJD, Dahmane N, O'Rourke DM, Davatzikos C.

Neuro Oncol. 2018 Jul 5;20(8):1068-1079. doi: 10.1093/neuonc/noy033.

23.

A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.

Windon AL, Loaiza-Bonilla A, Jensen CE, Randall M, Morrissette JJD, Shroff SG.

J Gastrointest Oncol. 2018 Feb;9(1):1-10. doi: 10.21037/jgo.2017.10.14.

24.

ROS1 Rearrangement in a Case of Classic Biphasic Pulmonary Blastoma.

Jenkins TM, Morrissette JJD, Kucharczuk JC, Deshpande CG.

Int J Surg Pathol. 2018 Jun;26(4):360-363. doi: 10.1177/1066896917749928. Epub 2018 Jan 2.

PMID:
29295663
25.

A Multicenter Phase I Study Evaluating Dual PI3K and BRAF Inhibition with PX-866 and Vemurafenib in Patients with Advanced BRAF V600-Mutant Solid Tumors.

Yam C, Xu X, Davies MA, Gimotty PA, Morrissette JJD, Tetzlaff MT, Wani KM, Liu S, Deng W, Buckley M, Zhao J, Amaravadi RK, Haas NB, Kudchadkar RR, Pavlick AC, Sosman JA, Tawbi H, Walker L, Schuchter LM, Karakousis GC, Gangadhar TC.

Clin Cancer Res. 2018 Jan 1;24(1):22-32. doi: 10.1158/1078-0432.CCR-17-1807. Epub 2017 Oct 19.

26.

Somatic HLA Mutations Expose the Role of Class I-Mediated Autoimmunity in Aplastic Anemia and its Clonal Complications.

Babushok DV, Duke JL, Xie HM, Stanley N, Atienza J, Perdigones N, Nicholas P, Ferriola D, Li Y, Huang H, Ye W, Morrissette JJD, Kearns J, Porter DL, Podsakoff GM, Eisenlohr LC, Biegel JA, Chou ST, Monos DS, Bessler M, Olson TS.

Blood Adv. 2017 Oct 10;1(22):1900-1910.

27.

BRCA locus-specific loss of heterozygosity in germline BRCA1 and BRCA2 carriers.

Maxwell KN, Wubbenhorst B, Wenz BM, De Sloover D, Pluta J, Emery L, Barrett A, Kraya AA, Anastopoulos IN, Yu S, Jiang Y, Chen H, Zhang NR, Hackman N, D'Andrea K, Daber R, Morrissette JJD, Mitra N, Feldman M, Domchek SM, Nathanson KL.

Nat Commun. 2017 Aug 22;8(1):319. doi: 10.1038/s41467-017-00388-9.

28.

Feasibility of monitoring advanced melanoma patients using cell-free DNA from plasma.

Gangadhar TC, Savitch SL, Yee SS, Xu W, Huang AC, Harmon S, Lieberman DB, Soucier D, Fan R, Black TA, Morrissette JJD, Salathia N, Waters J, Zhang S, Toung J, van Hummelen P, Fan JB, Xu X, Amaravadi RK, Schuchter LM, Karakousis GC, Hwang WT, Carpenter EL.

Pigment Cell Melanoma Res. 2018 Jan;31(1):73-81. doi: 10.1111/pcmr.12623. Epub 2017 Oct 23.

29.

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma.

O'Rourke DM, Nasrallah MP, Desai A, Melenhorst JJ, Mansfield K, Morrissette JJD, Martinez-Lage M, Brem S, Maloney E, Shen A, Isaacs R, Mohan S, Plesa G, Lacey SF, Navenot JM, Zheng Z, Levine BL, Okada H, June CH, Brogdon JL, Maus MV.

Sci Transl Med. 2017 Jul 19;9(399). pii: eaaa0984. doi: 10.1126/scitranslmed.aaa0984.

30.

Erratum to: Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):639-640. doi: 10.1007/s10549-017-4339-9. No abstract available.

PMID:
28653249
31.

Comparative clinical utility of tumor genomic testing and cell-free DNA in metastatic breast cancer.

Maxwell KN, Soucier-Ernst D, Tahirovic E, Troxel AB, Clark C, Feldman M, Colameco C, Kakrecha B, Langer M, Lieberman D, Morrissette JJD, Paul MR, Pan TC, Yee S, Shih N, Carpenter E, Chodosh LA, DeMichele A.

Breast Cancer Res Treat. 2017 Aug;164(3):627-638. doi: 10.1007/s10549-017-4257-x. Epub 2017 May 12. Erratum in: Breast Cancer Res Treat. 2017 Jun 26;:.

32.

Most Myeloid Neoplasms With Deletion of Chromosome 16q Are Distinct From Acute Myeloid Leukemia With Inv(16)(p13.1q22): A Bone Marrow Pathology Group Multicenter Study.

Rogers HJ, Hsi ED, Tang G, Wang SA, Bueso-Ramos CE, Lubin D, Morrissette JJ, Bagg A, Cherukuri DP, George TI, Peterson L, Liu YC, Mathew S, Orazi A, Hasserjian RP.

Am J Clin Pathol. 2017 Apr 1;147(4):411-419. doi: 10.1093/ajcp/aqx020.

PMID:
28375434
33.

Optimized depletion of chimeric antigen receptor T cells in murine xenograft models of human acute myeloid leukemia.

Tasian SK, Kenderian SS, Shen F, Ruella M, Shestova O, Kozlowski M, Li Y, Schrank-Hacker A, Morrissette JJD, Carroll M, June CH, Grupp SA, Gill S.

Blood. 2017 Apr 27;129(17):2395-2407. doi: 10.1182/blood-2016-08-736041. Epub 2017 Feb 28.

34.

Marginal zone lymphoma-derived interfollicular diffuse large B-cell lymphoma harboring 20q12 chromosomal deletion and missense mutation of BIRC3 gene: a case report.

Hatem J, Schrank-Hacker AM, Watt CD, Morrissette JJ, Rubin AI, Kim EJ, Nasta SD, Wasik MA, Bogusz AM.

Diagn Pathol. 2016 Dec 19;11(1):137.

35.

Next Generation Sequencing for the Detection of Actionable Mutations in Solid and Liquid Tumors.

Fox AJ, Hiemenz MC, Lieberman DB, Sukhadia S, Li B, Grubb J, Candrea P, Ganapathy K, Zhao J, Roth D, Alley E, Loren A, Morrissette JJ.

J Vis Exp. 2016 Sep 20;(115). doi: 10.3791/52758. Review.

36.

Dual CD19 and CD123 targeting prevents antigen-loss relapses after CD19-directed immunotherapies.

Ruella M, Barrett DM, Kenderian SS, Shestova O, Hofmann TJ, Perazzelli J, Klichinsky M, Aikawa V, Nazimuddin F, Kozlowski M, Scholler J, Lacey SF, Melenhorst JJ, Morrissette JJ, Christian DA, Hunter CA, Kalos M, Porter DL, June CH, Grupp SA, Gill S.

J Clin Invest. 2016 Oct 3;126(10):3814-3826. doi: 10.1172/JCI87366. Epub 2016 Aug 29.

37.

BRAF kinase domain mutations in de novo acute myeloid leukemia with monocytic differentiation.

Xu Y, Wertheim G, Morrissette JJ, Bagg A.

Leuk Lymphoma. 2017 Mar;58(3):743-745. doi: 10.1080/10428194.2016.1213830. Epub 2016 Aug 22. No abstract available.

PMID:
27545333
38.

Clinical Utility of Next-Generation Sequencing for Oncogenic Mutations in Patients with Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation.

Luskin MR, Carroll M, Lieberman D, Morrissette JJD, Zhao J, Crisalli L, Roth DB, Luger SM, Porter DL, Reshef R.

Biol Blood Marrow Transplant. 2016 Nov;22(11):1961-1967. doi: 10.1016/j.bbmt.2016.07.018. Epub 2016 Jul 28.

39.

A novel approach for next-generation sequencing of circulating tumor cells.

Yee SS, Lieberman DB, Blanchard T, Rader J, Zhao J, Troxel AB, DeSloover D, Fox AJ, Daber RD, Kakrecha B, Sukhadia S, Belka GK, DeMichele AM, Chodosh LA, Morrissette JJ, Carpenter EL.

Mol Genet Genomic Med. 2016 Feb 28;4(4):395-406. doi: 10.1002/mgg3.210. eCollection 2016 Jul.

40.

Detection of Molecular Alterations in Medullary Thyroid Carcinoma Using Next-Generation Sequencing: an Institutional Experience.

Wei S, LiVolsi VA, Montone KT, Morrissette JJ, Baloch ZW.

Endocr Pathol. 2016 Dec;27(4):359-362.

PMID:
27379493
41.

A Modified Integrated Genetic Model for Risk Prediction in Younger Patients with Acute Myeloid Leukemia.

Sloan CE, Luskin MR, Boccuti AM, Sehgal AR, Zhao J, Daber RD, Morrissette JJ, Luger SM, Bagg A, Gimotty PA, Carroll M.

PLoS One. 2016 Apr 6;11(4):e0153016. doi: 10.1371/journal.pone.0153016. eCollection 2016.

42.

Building a Robust Tumor Profiling Program: Synergy between Next-Generation Sequencing and Targeted Single-Gene Testing.

Hiemenz MC, Kadauke S, Lieberman DB, Roth DB, Zhao J, Watt CD, Daber RD, Morrissette JJ.

PLoS One. 2016 Apr 4;11(4):e0152851. doi: 10.1371/journal.pone.0152851. eCollection 2016.

43.

Familial Monosomy 7 Syndrome.

Morrissette JJD, Wertheim G, Olson T.

In: Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJH, Stephens K, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019.
2010 Jul 8 [updated 2016 Jan 21].

44.

Using "residual" FNA rinse and body fluid specimens for next-generation sequencing: An institutional experience.

Wei S, Lieberman D, Morrissette JJ, Baloch ZW, Roth DB, McGrath C.

Cancer Cytopathol. 2016 May;124(5):324-9. doi: 10.1002/cncy.21666. Epub 2015 Dec 18.

45.

STK11 Mutation Identified in Thyroid Carcinoma.

Wei S, LiVolsi VA, Brose MS, Montone KT, Morrissette JJ, Baloch ZW.

Endocr Pathol. 2016 Mar;27(1):65-9. doi: 10.1007/s12022-015-9411-6.

PMID:
26662608
46.

Transmission of an expanding donor-derived del(20q) clone through allogeneic hematopoietic stem cell transplantation without the development of a hematologic neoplasm.

Aikawa V, Porter D, Luskin MR, Bagg A, Morrissette JJ.

Cancer Genet. 2015 Dec;208(12):625-9. doi: 10.1016/j.cancergen.2015.10.003. Epub 2015 Nov 3.

PMID:
26628205
47.

PTEN and TP53 Mutations in Oncocytic Follicular Carcinoma.

Wei S, LiVolsi VA, Montone KT, Morrissette JJ, Baloch ZW.

Endocr Pathol. 2015 Dec;26(4):365-9. doi: 10.1007/s12022-015-9403-6.

PMID:
26530486
48.

Next-generation sequencing and personalized genomic medicine in hepatobiliary malignancies.

Loaiza-Bonilla A, Furth EE, Morrissette JJ.

Hepat Oncol. 2015 Oct;2(4):359-370. doi: 10.2217/hep.15.20. Epub 2015 Nov 11. Review.

49.

Multiple Gastrointestinal Polyps in Patients Treated with BRAF Inhibitors.

Amaravadi RK, Hamilton KE, Ma X, Piao S, Portillo AD, Nathanson KL, Carlino MS, Long GV, Puzanov I, Xu X, Morrissette JJ, Tsai KY, Flaherty KT, Sosman JA, Goodman GR, McArthur GA, Rustgi AK, Metz DC, Schuchter LM, Chapman PB, Sepulveda AR.

Clin Cancer Res. 2015 Dec 1;21(23):5215-21. doi: 10.1158/1078-0432.CCR-15-0469. Epub 2015 Jul 22.

50.

NPM1 mutation is associated with leukemia cutis in acute myeloid leukemia with monocytic features.

Luskin MR, Huen AO, Brooks SA, Stewart C, Watt CD, Morrissette JJ, Lieberman DB, Bagg A, Rosenbach M, Perl AE.

Haematologica. 2015 Oct;100(10):e412-4. doi: 10.3324/haematol.2015.129346. Epub 2015 Jun 25. No abstract available.

Supplemental Content

Loading ...
Support Center